全文获取类型
收费全文 | 522篇 |
免费 | 32篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 14篇 |
妇产科学 | 2篇 |
基础医学 | 67篇 |
口腔科学 | 10篇 |
临床医学 | 21篇 |
内科学 | 42篇 |
皮肤病学 | 38篇 |
神经病学 | 4篇 |
特种医学 | 21篇 |
外科学 | 30篇 |
综合类 | 110篇 |
预防医学 | 2篇 |
眼科学 | 3篇 |
药学 | 94篇 |
1篇 | |
中国医学 | 34篇 |
肿瘤学 | 75篇 |
出版年
2024年 | 4篇 |
2023年 | 5篇 |
2022年 | 8篇 |
2021年 | 11篇 |
2020年 | 13篇 |
2019年 | 14篇 |
2018年 | 19篇 |
2017年 | 9篇 |
2016年 | 15篇 |
2015年 | 22篇 |
2014年 | 29篇 |
2013年 | 47篇 |
2012年 | 31篇 |
2011年 | 22篇 |
2010年 | 27篇 |
2009年 | 21篇 |
2008年 | 27篇 |
2007年 | 23篇 |
2006年 | 21篇 |
2005年 | 22篇 |
2004年 | 22篇 |
2003年 | 21篇 |
2002年 | 17篇 |
2001年 | 16篇 |
2000年 | 11篇 |
1999年 | 6篇 |
1998年 | 9篇 |
1997年 | 9篇 |
1996年 | 8篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 7篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 4篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
排序方式: 共有578条查询结果,搜索用时 46 毫秒
1.
Yoshinori Yamashita Toshihiro Hirai Hidenori Mukaida Takashi Iwata Tetsuya Toge Hong Jae Hoon 《Surgery today》1990,20(6):671-676
This report presents the effect of repeated heating every 24 hrs using bleomycin (BLM) which, although seemingly contrary
to the usual agreement that hyperthermia should be carried out with a long interval due to thermotolerance, holds many possibilities.
FM3A cells on the foot pad of C3H mouse were immersed in a heated water bath at 43 and 44°C for 30 min. The effect of repeated
heating was appreciated by an improved growth curve and 50 day survival compared to mice which received heating twice with
a 96-hr interval. Repeated heating every 24 hrs 5 times with BLM suppressed tumor growth significantly as compared to heating
twice with a 96-hr interval without BLM. The longest survival time was obtained by the repeated heating with BLM among all
protocols. There is therefore a good possibility that more effective results could be obtained clinically by repeated heating
over a short period. 相似文献
2.
KAR NENG LAI JOSEPH W. C. LEUNG PAUL N. M. CHENG FERNAND MAC-MOUNE LAI 《Journal of gastroenterology and hepatology》1987,2(5):467-472
Dialytic ultrafiltration with haemofilter was performed in 16 patients with malignant ascites refractory to treatment with sodium restriction, diuretic and systemic chemotherapy. A continuous flow of ascitic fluid at a rate of 300–400 ml/min through a haemofilter was maintained by a blood pump. The protein-rich ascitic fluid was re-infused into the peritoneal cavity with sodium and water removed. An average of 5.2 1 of filtrate was removed over a mean interval of 3.5 h. Bleomycin (60 mg) was administered intraperitoneally following the procedure. Complete response was observed in six patients (37.25%) and partial response occurred in four (25%). The remaining patients showed no response. Complications of the dialytic ultrafiltration procedure and toxicity of intraperitoneal administration of bleomycin were minimal. The technique of dialytic ultrafiltration is simple, safe and cost-effective and could be used as an adjuvant therapy for intraperitoneal chemotherapy. 相似文献
3.
Electrochemotherapy is a novel antitumor treatment involving the systemic administration of bleomycin followed by the delivery
of electrical pulses to the tumor. The present study investigates the effects of electrochemotherapy on the growth of colon
26 cells inoculated subcutaneously into the backs of BALB/c mice. The mice were divided into the following four experimental
groups: 20 that received no further treatment after the inoculation of colon 26 cells (control group); 20 that received 500
μg of bleomycin intraperitoneally 7 and 9 days after the inoculation (BLM group); 20 that received electric pulses to the
tumor 7 and 9 days after the inoculation (EP group); and 30 that received electrochemotherapy 7 and 9 days after the inoculation
(ECT group). During 28 days of observation, no deaths due to tumor progression occurred in the ECT group, but there were 18
in the control group, 11 in the BLM group, and 18 in the EP group. While weight loss was observed in all groups, it was most
remarkable in the control group. Tumor growth was significantly inhibited in the ECT group, compared to the other experimental
groups (P<0.01). The results of this study demonstrated that electrochemotherapy significantly inhibited the growth of colon 26 tumors
in mice, without causing any remarkable adverse effects. 相似文献
4.
益肺抗纤方对博莱霉素诱导大鼠肺纤维化的防治作用 总被引:4,自引:0,他引:4
目的 :观察益肺抗纤方抗肺纤维化的作用。方法 :实验用雄性Wistar大鼠分为 4组 ,对照组、模型组、益肺抗纤方组、地塞米松组 ;对照组气管内注入生理盐水 ,其余 3组气管内注入博莱霉素制作大鼠肺纤维化模型。造模后 ,益肺抗纤方组给益肺抗纤方 10ml/kg灌胃 ,地塞米松组给地塞米松 1.5mg/kg腹腔注射 ,模型组和对照组均给生理盐水灌胃 ,均给药 1次 /d。观察各组大鼠肺部病理变化 ,测定各组第 7d、2 8d肺组织超氧化物歧化酶(SOD)、脂质过氧化物 (LPO)和羟脯氨酸 (HP)的含量。结果 :气管内注入博莱霉素第 2 8d时 ,模型组多呈 3级肺纤维化和 1级肺泡炎改变 ;益肺抗纤方组多呈 1级纤维化改变 ,肺泡炎不明显 ;地塞米松组多呈 1级纤维化和 1~ 3级肺泡炎改变 ;对照组呈正常肺结构。第 2 8d时 ,模型组和地塞米松组肺组织SOD活性均较对照组明显下降 (P <0 .0 1和P <0 .0 5 ) ,地塞米松组较模型组SOD活性下降更明显 (P <0 .0 5 ) ;益肺抗纤方组与对照组之间SOD活性无明显差别。对照组、模型组、益肺抗纤方组肺组织LPO含量明显低于地塞米松组 (P <0 .0 1) ;益肺抗纤方组与对照组和模型组之间无明显差别。结论 :益肺抗纤方可通过提高SOD活性 ,降低脂质过氧化 ,减轻氧自由基损伤 ,抑制胶原沉积 ,保护肺组织 相似文献
5.
平阳霉素治疗血管瘤、血管畸形后组织学观察 总被引:15,自引:0,他引:15
目的 :观察平阳霉素治疗血管瘤、血管畸形后引起的组织学变化。方法 :13例不同类型的血管病变 ,分1~ 3次注射平阳霉素 4~ 2 4mg ,多次注射者间隔 10~ 12d .在末次注射后 12~ 15d切除治疗后的病变组织进行组织学观察。结果 :注射 1次的标本中血管壁增厚 ,管腔变狭窄 ;注射 2次的标本中管腔闭塞 ,管壁失去正常结构 ;注射 3次的标本中管壁结构消失 ,组织纤维化。结论 :平阳霉素瘤腔内注射后可引起血管内膜变化 ,致使管腔闭塞 ,从而治愈血管瘤及血管畸形 相似文献
6.
Bruce F. Kimler Changnian Liu Richard G. Evans Robert A. Morantz 《Journal of neuro-oncology》1992,14(3):191-200
Summary We have used the 9L rat brain tumor model to search for effective chemotherapeutic approaches to the management of brain tumors. Several antineoplastic agents which have been proposed or are currently being used for human brain tumors, including 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), bleomycin, aziridinylbenzoquinone (AZQ), cis-Platinum, and acivicin, were administered intravenously (iv), intraperitoneally (ip), or intracerebrally (ic) to rats burdened with the intracranial 9L gliosarcoma. The results confirm that BCNU is the most effective systemic agent among the chemotherapeutic agents tested as indicated by its ability to significantly increase the median survival time (MST) and life span of the tumor-burdened animals. Bleomycin is an effective agent against the intracranial 9L tumor when administered ic. While neither systemic single iv dose AZQ (0.5–2.5 mg/kg) nor multiple ip treatments (0.5–1.0 mg/kg × 5, q 6 h) were effective in prolonging the survival, single is dose AZQ (5–50 g/rat) treatment significantly increased the MST of the treated animals (P < 0.05). Systemic AZQ treatments using higher doses produced a hematological toxicity, resulting in a decrease in MST of the treated animals. Cis-Platinum, either administered ip or ic, produced only a marginal effect on survival, although acute neurologic toxicity limited the dose of cis-Patinum that could be administered ic. Acivicin, either administered ip or ic, produced no effect on the survival of treated animals. Our results suggest that local treatment with certain antineoplastic agents may be an efficient therapy in the management of brain tumors. 相似文献
7.
Background: Cisplatin (CDDP) and 5-fluorouracil (5-FU) represent the standard chemotherapy for advanced/recurrent head and neck squamous carcinoma (HNSC); however, the duration of response is often short, with a median survival of only five to six months.Patients and methods: Patients with HNSC were treated with vinorelbine 20 mg/m2 and methotrexate 50 mg/m2 every week and bleomycin 15 mg/m2 every two weeks. All patients were previously treated with a CDDP/5-FU regimen.Results: Forty-eight patients were evaluable for response and toxicity. After a median follow-up of 15 months, 16 patients are still alive and 32 have died. We had one complete response (2%), 12 partial responses (25%) (overall response rate 27%; 95% CI: 14%–39%), 11 stabilizations (23%) and 24 progressions (50%) of disease. Neutropenia grade 3–4 was seen in 12 patients; peripheral neurotoxicity in two patients. There were no toxic deaths.Conclusions: This regimen, administered in an outpatient setting, revealed some activity as a second-line treatment in patients with HNSC, with acceptable toxicity. 相似文献
8.
丹参对博莱霉素所致大鼠肺纤维化保护作用的实验研究 总被引:9,自引:0,他引:9
目的:探讨丹参对博莱霉素所致大鼠肺纤维化的保护作用及其作用机理.方法:通过气管内注射博莱霉素复制大鼠肺纤维化模型,在造模后的d 1和d 7开始给予丹参注射液治疗,分别在d 7、d 28处死大鼠,对肺组织匀浆中的脂质过氧化物(MDA)、谷胱甘肽(GSH)、羟脯氨酸(HYP)和肺组织病理学变化测量.结果:在造模后d 1给予丹参注射液治疗能抑制实验性肺纤维化大鼠的肺组织匀浆中的MDA、HYP异常升高和GSH的下降,减轻其肺部的病理损害;在造模后d 7给予丹参注射液治疗,丹参治疗组与模型组上述观察指标比较无统计学差异.结论:丹参注射液可预防大鼠肺纤维化,对已形成的肺纤维化无逆转作用. 相似文献
9.
A. Sindel A. Sayan Ö. Özgür T. Sindel V. Ilankovan 《The British journal of oral & maxillofacial surgery》2018,56(3):206-211
The aim of this study was to evaluate the efficacy of fluoroscopy-guided percutaneous injection of bleomycin as the primary treatment for low-flow vascular malformations. A total of 34 patients (mean (range) age 24 (8–51) years) with orofacial vascular lesions were treated in the Department of Interventional Radiology and Maxillofacial Surgery. There were 20 low-flow venous malformations, 11 lymphatic malformations, and three of mixed type. All patients were treated by fluoroscopy-guided percutaneous injection of a mixture of bleomycin (mean (range) 15 (5–15) mg) and a radio-opaque agent (Ultravist® (iopromide), Bayer)/session. The number of sessions ranged from one to six. The clinical response was complete in 21 patients, obvious in nine, and of clinical benefit in four. Patients were reviewed within the first week, third week, and at three-month periods until 24 months. There were no serious complications such as pulmonary fibrosis. Fluoroscopy-guided intralesional injection of bleomycin should be considered as the first-line treatment for lymphatic malformations because it is effective and reliable with few complications. 相似文献
10.
《Expert review of anticancer therapy》2013,13(5):671-678
Electroporation is a novel therapeutic modality that uses pulsed electrical currents to enhance the uptake of drugs, vaccines and genes into cells, and has been used for over 20 years. Electroporation therapy using cytotoxic drugs is called electrochemotherapy. Electrochemotherapy has been studied in vitro, in vivo and in clinical trials. It is potentially useful for treating patients with metastatic tumors, such as melanoma, and even select primary tumors, such as head and neck squamous cell carcinomas and basal cell carcinoma. Various chemotherapeutic agents have been tested with electroporation therapy, but bleomycin and cisplatin are the two most widely used. The biological basis of electroporation therapy is outlined in this review and basic science studies and the limited clinical studies that have involved electrochemotherapy are reviewed. Particular focus is placed on trials involving melanoma, head and neck cancers and other primary and metastatic skin cancers. 相似文献